Get the Stockscreener App
0.00
100.00%
-15.50
Dynavax Technologies Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
See More
Previous Close:
$15.50
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.76B
Revenue:
$260.81M
Net Income/Loss:
$20.48M
P/E Ratio:
0.00
EPS:
0.13
Net Cash Flow:
$22.67M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.73
Dynavax Technologies Corp Stock (DVAX) Company Profile
Name
Dynavax Technologies Corp
Sector
Phone
(510) 848-5100
Address
2100 POWELL STREET, EMERYVILLE, CA
Compare DVAX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DVAX
Dynavax Technologies Corp
|
0.00 | 1.76B | 260.81M | 20.48M | 22.67M | 0.13 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 58.51B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.70 | 49.90B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.975 | 44.64B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.42 | 35.08B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
585.52 | 25.99B | 3.18B | 1.33B | 1.04B | 27.90 |
Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-01-24 | Initiated | Goldman | Neutral |
| Sep-27-22 | Initiated | JMP Securities | Mkt Outperform |
| Jan-06-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Initiated | Goldman | Buy |
| Aug-07-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-20 | Initiated | Evercore ISI | Outperform |
| Oct-18-19 | Initiated | H.C. Wainwright | Buy |
| Jul-11-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-27-19 | Reiterated | Cantor Fitzgerald | Overweight |
| May-10-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-25-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-31-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-31-17 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Apr-28-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-27-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-13 | Upgrade | MLV & Co | Hold → Buy |
| Feb-25-13 | Downgrade | MLV & Co | Buy → Hold |
| Nov-16-12 | Reiterated | MLV & Co | Buy |
View All
Dynavax Technologies Corp Stock (DVAX) Latest News
DVAX SEC FilingsDynavax Technolo 10-K, 10-Q, 8-K Forms - Stock Titan
Dynavax Technologies Stock (ISIN: US2681581009) Nears 52-Week High Amid Vaccine Revenue Momentum - AD HOC NEWS
Dynavax Technologies Stock (ISIN: US2681581009) Eyes Steady Gains Amid Biotech Momentum and Revenue - AD HOC NEWS
Growth Report: Does Dynavax Technologies Corporation stock have upside surprise potential2026 Key Lessons & Growth Oriented Trading Recommendations - baoquankhu1.vn
Dynavax Technologies Stock Surges on Vaxart Partnership Validation and Analyst Upside - AD HOC NEWS
Rhenman & Partners Asset Management Boosts Stake in Dynavax Technologies - National Today
Published on: 2026-03-07 01:32:59 - baoquankhu1.vn
USA Herald - USA Herald
DVAX Technical Analysis & ETF Price Forecast - Intellectia AI
[15-12G] DYNAVAX TECHNOLOGIES CORP SEC Filing - Stock Titan
M&A activity drives infectious disease stock rebound - BioWorld MedTech
Can Dynavax Technologies Corporation (DYF1) stock surprise with quarterly resultsJuly 2025 Opening Moves & Safe Capital Investment Plans - mfd.ru
Merger Talk: Does Mangoceuticals Inc have a sustainable dividendJuly 2025 Reactions & Expert Curated Trade Ideas - baoquankhu1.vn
Dynavax Technologies (DVAX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dynavax Technologies Leads Six-Month Stock Returns with 50.05% Gain - Markets Mojo
Sanofi Buyout Ends Dynavax Listing And Shifts Vaccine Upside To Group - Yahoo Finance
A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates - Yahoo Finance
Is It Time To Reassess Dynavax (DVAX) After The Agreed Sanofi Cash Acquisition Deal - Yahoo Finance
Sanofi Concludes $2.2 Billion Takeover of Dynavax Technologies - marketscreener.com
Sanofi completes acquisition of Dynavax Technologies, triggers Nasdaq delisting - Investing.com
Dynavax Technologies Announces Board and Officer Changes Following Merger - TradingView
Sanofi closes Dynavax (NASDAQ: DVAX) takeover, delisting shares at $15.50 cash - Stock Titan
Press Release: Sanofi completes the acquisition of Dynavax - Yahoo Finance
Sanofi to merge Dynavax (NASDAQ: DVAX) after $15.50 per share cash tender - Stock Titan
Dynavax Completes Merger and Prepares Nasdaq Delisting - TipRanks
Sanofi Bolsters Vaccine Portfolio with Major Dynavax Acquisition - AD HOC NEWS
Profit Recap: What hedge funds are buying Primech Holdings LtdPortfolio Risk Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Dynavax Technologies Corporation (NASDAQ:DVAX) Receives $24.33 Average Price Target from Analysts - Defense World
Trading Action: Is Dynavax Technologies Corporation forming a bullish divergenceWeekly Profit Report & Low Risk Entry Point Tips - baoquankhu1.vn
DVAX Should I Buy - Intellectia AI
Short Interest in Dynavax Technologies Corporation (NASDAQ:DVAX) Declines By 14.0% - MarketBeat
Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment - simplywall.st
AlphaQuest LLC Boosts Stock Position in Dynavax Technologies Corporation $DVAX - Defense World
Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders - simplywall.st
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - AOL.com
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - The Motley Fool
Sanofi (DVAX) tender offer wins antitrust clearance as shareholders sue - stocktitan.net
Sanofi tender offer progresses; Dynavax (NASDAQ: DVAX) discloses insider holdings and litigation - Stock Titan
Signal Recap: Does Dynavax Technologies Corporation stock have upside surprise potentialJuly 2025 Gainers & AI Driven Stock Movement Reports - baoquankhu1.vn
Dynavax president Novack sells $1.78m in shares - Investing.com
Dynavax CEO ignored last-minute suitor's email after signing $2.2 billion Sanofi deal - The Business Journals
Dynavax Technologies (NASDAQ:DVAX) Stock Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Ocular Therapeutix Rejects Sanofi's Bid, Stock Surges 13% - Intellectia AI
Jim Cramer Highlights Sanofi's Bid for Dynavax - Finviz
Jim Cramer Highlights Sanofi’s Bid for Dynavax - Insider Monkey
Dynavax Technologies Corporation (DVAX) Investor Outlook: Exploring a 30.74% Potential Upside - DirectorsTalk Interviews
Dynavax Shares Surge as Acquisition Battle Looms - AD HOC NEWS
Dynavax (DVAX) Shares Rise 1.9% as New Bidder Emerges Post-Sanofi Deal - Intellectia AI
Dynavax Technologies (NASDAQ:DVAX) Sets New 12-Month HighStill a Buy? - MarketBeat
Dynavax gains on disclosure another bidder interested after deal announced (DVAX:NASDAQ) - Seeking Alpha
Dynavax Technologies stock hits 52-week high at $15.68 - Investing.com
Dynavax Technologies Corp Stock (DVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):